Track SLNO and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Soleno Therapeutics Inc
100 Marine Parkway, Redwood City, CA, United States, 94065
IPO
2014
Employees
182
Industry
Biotechnology
Sector
Healthcare
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20251-1
0
Q2 20251-1
0
2-quarter cumulative
2 sells0 buys
Analyst Ratings
3 analysts covering
Buy100%recommend buy
Buy
3
Hold
0
Sell
0